Affiliation: Saarland University
- Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSFM Pfreundschuh
Department of Medicine, Saarland University Medical School, Germany
Ann Oncol 12:471-7. 2001..The use of CSF for interval reduction rather than dose escalation is the more effective strategy for dose intensification...
- Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)M Pfreundschuh
Saarland University Medical School, Homburg, Germany
Ann Oncol 19:545-52. 2008....
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh
Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
Lancet Oncol 9:105-16. 2008..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
- Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopeniaC Zwick
Department of Oncology, Saarland University Medical School, Homburg, Germany
Ann Oncol 22:1872-7. 2011..To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia...
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupMichael Pfreundschuh
Universitatsklinikum des Saarlandes, Homburg, Germany
Lancet Oncol 12:1013-22. 2011..Extended follow-up was needed to establish long-term effects...
- Tumour vaccines: a new immunotherapeutic approach in oncologyC Renner
Med Dept I, Saarland University Medical School, Homburg Saar, Germany
Ann Hematol 79:651-9. 2000..However, we are still at the beginning of this process and should always remember that only well-designed, prospective clinical trials can define the optimal use of tumour vaccines in oncology...
- [Treatment of hematological malignancies with monoclonal antibodies]G Held
Klinik und Poliklinik für Innere Medizin I, Universitatsklinikum des Saarlandes, Homburg Saar, 66421, Homburg, Germany
Internist (Berl) 49:929-30, 932-4, 936-7. 2008..In this review the current role of monoclonal antibodies in the treatment of different hematological neoplasms will be discussed and perspectives for their future use in leukemia and lymphomas will be shown...
- Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feetP Simon
Department of Oncology and Rheumatology, Saarland University Medical School, D 66421 Homburg, Germany
Clin Exp Rheumatol 30:45-50. 2012..The aim of this study was to determine clinical factors as possible predictors for radiological damage in hands and feet of PsA patients with a 12-month follow-up...
- A novel system to test for specificity of B cell receptors from tissue of Wegener's granulomatosis patientsJ Voswinkel
Saarland University Medical School, Internal Medicine I, Homburg Saar, Germany
Clin Exp Rheumatol 26:S90-6. 2008..These fab fragments have the identical antigen binding site like the B-cell receptor from which the DNA was derived...
- Serological identification of human tumor antigensU Sahin
Medizinische Klinik I, Universitat des Saarlandes, Homburg, Germany
Curr Opin Immunol 9:709-16. 1997..The abundance of serologically defined human tumor antigens facilitates the identification of T cell dependent antigens and provides a basis for peptide and gene therapy vaccine strategies in a wide variety of human cancers...
- Exploitation of the B cell repertoire for the identification of human tumor antigensM Pfreundschuh
Department of Medicine, Saarland University Medical School, Homburg, Germany
Cancer Chemother Pharmacol 46:S3-7. 2000..Finally, many of the antigens identified using SEREX seem to play a functional role in the pathogenesis of malignant disease...
- Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo systemC Renner
Medical Department I, Saarland University, Homburg, Germany
Cancer Immunol Immunother 50:102-8. 2001....
- Clinical approaches to vaccination in oncologyC Renner
Medical Department I, Saarland University Medical School, Homburg Saar, Germany
Ann Hematol 80:255-66. 2001..The precise definition of immune parameters in these patients will then lead the way for optimised treatment procedures that might even be beneficial for a larger group of cancer patients...
- Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)V Boehme
Department of Haematology, General Hospital St Georg, Hamburg, and Institute of Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany
Ann Oncol 18:149-57. 2007....
- [Treatment of diffuse large B-cell lymphoma]B Gleissner
Klinik fur Innere Medizin I, Universitätsklinikum Saarland, Homburg
Dtsch Med Wochenschr 133:1785-94; quiz 1795-6. 2008....
- Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)A Wunderlich
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
Ann Oncol 14:881-93. 2003..To enable more extensive testing of these schemes we here characterise their practicability regarding schedule adherence, acute haematotoxicity and need for supportive treatment...
- Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimensL Trumper
Hematology and Oncology, University Hospital Gottingen, Germany
Ann Oncol 19:538-44. 2008..To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support...
- Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphomaM Ziepert
Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
Ann Oncol 19:752-62. 2008..Little is known on the heterogeneity of hematotoxicity in patients receiving multicycle chemotherapy...
- Advances in molecular biology diagnostic and treatment of B-cell malignanciesR Schmits
Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
Ann Oncol 16:ii105. 2005
- [Treatment of aggressive lymphomas]B Gleissner
Medizinische Klinik I, Universitätsklinikum Saarland, Kirrberger Strasse, 66421, Homburg, Deutschland
Internist (Berl) 48:389-95. 2007..For patients > 60 years from all IPI groups, the best results have so far been achieved with six courses of R-CHOP-14 followed by two additional applications of rituximab...
- Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokinesF Hartmann
Department of Medicine, Saarland University Medical School D-66421 Homburg, Germany
Clin Cancer Res 7:1873-81. 2001..Coadministration of cytokines might contribute to an augmented antitumor activity, and additional clinical trials are warranted to optimize this novel treatment modality...
- [New diagnostic and therapeutic strategies for aggressive lymphomas]L Trumper
Abteilung Hämatologie und Onkologie, Klinikum der Georg August Universität, Gottingen
Dtsch Med Wochenschr 129:2113-7. 2004
- A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaF Morschhauser
Hematology, Hopital C Huriez Centre Hospitalier Universitaire, Lille, France
Ann Oncol 19:247-53. 2008..Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCbeta/PI3K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis...